Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ACOs Stakeholders Are "Flying And Building The Plane At The Same Time"

Executive Summary

CMS officials are acknowledging the challenges health care industry stakeholders face in embracing accountable care organizations while federal regulations governing the program are still in flux.

You may also be interested in...



Pharma’s Latest Challenge: 
What To Do About New Provider-Payer Business Models

Even though their specifics are not widely known, the concepts of Medicare's accountable care organizations and other payer-provider linkups are spurring change in the pharmaceutical industry's commercial landscape.

Pharma’s Latest Challenge: 
What To Do About New Provider-Payer Business Models

Even though their specifics are not widely known, the concepts of Medicare's accountable care organizations and other payer-provider linkups are spurring change in the pharmaceutical industry's commercial landscape.

If They Build It, Will Anybody Come?

Health systems are telling CMS that, as proposed in the agency's draft rule, the Medicare accountable care organization program may not attract participants. Those types of comments are coming even from health systems that have been touted as the types of organizations that are already doing many of the activities envisioned for Medicare ACOs, such as coordinating patient care between providers and assessing provider performance through a list of defined outcome measures, and so had been thought most likely to sign up.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel